Bayer Group To Intensify Health Care Investment In China
This article was originally published in PharmAsia News
Executive Summary
Bayer Group China recently revealed that the group will increase investment for its three business sectors-m aterial science, health care and crop science-over the next few years. The proportion of allocation will depend on the market development strategy under preparation and upcoming policies in China. The group will step up efforts in health care while it will slow down the pace for material science, currently its largest and most established sector in China. Besides importing technology, Bayer's health care in China will actively look for acquisitions or mergers, and expand funding in drug labs and clinical trials. In addition, the firm plans to launch about 20 medicines in China within the next five years. (Click here for more - Chinese Language)
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.